Enacts the "foreign drug transparency act" to provide information on the origin, manufacture and distribution of prescription drugs; requires a pharmacy benefit manager to maintain, and make available to pharmacies, health plans, and patients upon request, supply chain information for prescription drugs covered under its network.
S T A T E O F N E W Y O R K
________________________________________________________________________
10967
I N A S S E M B L Y
April 14, 2026
___________
Introduced by M. of A. BLUMENCRANZ -- read once and referred to the
Committee on Health
AN ACT to amend the public health law and the education law, in relation
to enhancing transparency in the prescription drug supply chain,
including disclosure of country of origin and manufacturer information
THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
BLY, DO ENACT AS FOLLOWS:
Section 1. This act shall be entitled the "foreign drug transparency
act".
§ 2. Legislative intent. The legislature hereby finds and declares
that:
1. The United States prescription drug supply chain is increasingly
globalized, with a significant portion of finished drug products and
active pharmaceutical ingredients (APIs) manufactured outside of the
United States.
2. Patients, pharmacists, and health care providers often lack access
to clear and accessible information regarding the origin and manufactur-
ing of prescription drugs.
3. Transparency regarding the origin, manufacture, and distribution of
prescription drugs is essential to ensuring patient confidence, informed
decision-making, and supply chain accountability.
4. The legislature recognizes and supports ongoing bipartisan federal
efforts, including the CLEAR LABELS Act, to require disclosure of drug
manufacturing and supply chain information.
5. It is the intent of this act to complement federal law by ensuring
that such information is readily accessible to consumers at the point of
dispensing within New York State.
§ 3. Subdivision 1 of section 280-a of the public health law is
amended by adding three new paragraphs (j), (k), and (l) to read as
follows:
(J) "ACTIVE PHARMACEUTICAL INGREDIENT" OR "API" MEANS ANY SUBSTANCE OR
COMPONENT INTENDED TO FURNISH PHARMACOLOGICAL ACTIVITY IN THE DIAGNOSIS,
CURE, MITIGATION, TREATMENT, OR PREVENTION OF DISEASE.
EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD15453-01-6
Open Legislation is a forum for New York State legislation. All comments are subject to review and community moderation is encouraged.
Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity, hate or toxic speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Attempts to intimidate and silence contributors or deliberately deceive the public, including excessive or extraneous posting/posts, or coordinated activity, are prohibited and may result in the temporary or permanent banning of the user. Comment moderation is generally performed Monday through Friday. By contributing or voting you agree to the Terms of Participation and verify you are over 13.
Create an account. An account allows you to sign petitions with a single click, officially support or oppose key legislation, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.